• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Treatment of anorexia and weight loss with megestrol acetate in patients with cancer or acquired immunodeficiency syndrome.

作者信息

Tchekmedyian N S, Hickman M, Heber D

机构信息

Pacific Coast Hematology/Oncology Medical Group, Long Beach, CA.

出版信息

Semin Oncol. 1991 Feb;18(1 Suppl 2):35-42.

PMID:1992535
Abstract

Anorexia is a symptom of cancer and a cause of decreased caloric intake and weight loss. Successful treatment for anorexia can improve the patient's well-being and prevent or reverse the effects of anorexia on nutrition. Following reports of appetite enhancement and weight gain in uncontrolled studies of high-dose (320 to 1,600 mg/d) megestrol acetate in patients with cancer or AIDS (acquired immunodeficiency syndrome), several randomized, placebo-controlled trials have been completed. These trials demonstrate that megestrol acetate therapy improves appetite and food intake in patients with anorexia and advanced cancer, leading to weight gain in a subset of patients. The mechanisms of action of megestrol acetate (a progesterone derivative) probably include both behavioral and metabolic effects. Several carefully designed randomized trials are under way to establish the optimal dose and to determine the mechanism of weight gain. Patients with cancer or AIDS who complain of anorexia and whose nutritional status is compromised may benefit from megestrol acetate therapy.

摘要

相似文献

1
Treatment of anorexia and weight loss with megestrol acetate in patients with cancer or acquired immunodeficiency syndrome.
Semin Oncol. 1991 Feb;18(1 Suppl 2):35-42.
2
Treatment of anorexia with megestrol acetate.醋酸甲地孕酮治疗厌食症。
Nutr Clin Pract. 1993 Jun;8(3):115-8. doi: 10.1177/0115426593008003115.
3
Randomized trials of megestrol acetate for AIDS-associated anorexia and cachexia.醋酸甲地孕酮治疗艾滋病相关厌食和恶病质的随机试验。
Oncology. 1994 Oct;51 Suppl 1:19-24. doi: 10.1159/000227411.
4
Treatment of cancer anorexia with megestrol acetate: which is the optimal dose?醋酸甲地孕酮治疗癌症厌食症:最佳剂量是多少?
J Natl Cancer Inst. 1991 Mar 20;83(6):449-50. doi: 10.1093/jnci/83.6.449.
5
Megestrol acetate for treatment of anorexia and cachexia associated with human immunodeficiency virus infection.醋酸甲地孕酮用于治疗与人类免疫缺陷病毒感染相关的厌食和恶病质。
Semin Oncol. 1990 Dec;17(6 Suppl 9):13-6.
6
Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia.醋酸甲地孕酮治疗癌症厌食和恶病质的对照试验。
J Natl Cancer Inst. 1990 Jul 4;82(13):1127-32. doi: 10.1093/jnci/82.13.1127.
7
Megestrol acetate for anorexia and cachexia.醋酸甲地孕酮用于治疗厌食和恶病质。
Oncology. 1992;49 Suppl 2:46-9. doi: 10.1159/000227128.
8
Megestrol acetate for the treatment of anorexia-cachexia syndrome.醋酸甲地孕酮治疗恶病质综合征。
Cochrane Database Syst Rev. 2005 Apr 18(2):CD004310. doi: 10.1002/14651858.CD004310.pub2.
9
Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia.四剂醋酸甲地孕酮治疗癌症厌食和/或恶病质患者的III期评估。
J Clin Oncol. 1993 Apr;11(4):762-7. doi: 10.1200/JCO.1993.11.4.762.
10
Megestrol acetate in patients with AIDS and cachexia.醋酸甲地孕酮用于艾滋病和恶病质患者。
Ann Intern Med. 1994 Sep 15;121(6):400-8. doi: 10.7326/0003-4819-121-6-199409150-00002.

引用本文的文献

1
Megestrol acetate for treatment of anorexia-cachexia syndrome.醋酸甲地孕酮治疗恶病质综合征。
Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD004310. doi: 10.1002/14651858.CD004310.pub3.
2
Megestrol acetate in cachexia and anorexia.醋酸甲地孕酮用于恶病质和厌食症。
Int J Nanomedicine. 2006;1(4):411-6. doi: 10.2147/nano.2006.1.4.411.
3
Efficacy and economics of hormonal therapies for advanced breast cancer.晚期乳腺癌激素疗法的疗效与经济学分析
Drugs Aging. 2002;19(6):453-63. doi: 10.2165/00002512-200219060-00004.
4
Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate.
Cancer Chemother Pharmacol. 1994;34(2):96-102. doi: 10.1007/BF00685925.